Fine-tuning T Cell Function Through Engineered Orthogonal Chimeric Cytokine Receptors

Overview

Journal Cell Res

Specialty Cell Biology

Date 2022 Aug 24

PMID 36002586

Authors

Rigel J Kishton

Nicholas P Restifo

Affiliations

Soon will be listed here.

References

Klebanoff C, Khong H, Antony P, Palmer D, Restifo N . Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005; 26(2):111-7. PMC: 1388277. DOI: 10.1016/j.it.2004.12.003. View

van der Windt G, Everts B, Chang C, Curtis J, Freitas T, Amiel E . Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity. 2011; 36(1):68-78. PMC: 3269311. DOI: 10.1016/j.immuni.2011.12.007. View

Kalbasi A, Siurala M, Su L, Tariveranmoshabad M, Picton L, Ravikumar P . Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature. 2022; 607(7918):360-365. PMC: 9283313. DOI: 10.1038/s41586-022-04801-2. View

Mo F, Yu Z, Li P, Oh J, Spolski R, Zhao L . An engineered IL-2 partial agonist promotes CD8 T cell stemness. Nature. 2021; 597(7877):544-548. PMC: 9172917. DOI: 10.1038/s41586-021-03861-0. View

Klebanoff C, Finkelstein S, Surman D, Lichtman M, Gattinoni L, Theoret M . IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A. 2004; 101(7):1969-74. PMC: 357036. DOI: 10.1073/pnas.0307298101. View

Hinrichs C, Spolski R, Paulos C, Gattinoni L, Kerstann K, Palmer D . IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 2008; 111(11):5326-33. PMC: 2396726. DOI: 10.1182/blood-2007-09-113050. View

Curtsinger J, Mescher M . Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010; 22(3):333-40. PMC: 2891062. DOI: 10.1016/j.coi.2010.02.013. View

Sockolosky J, Trotta E, Parisi G, Picton L, Su L, Le A . Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018; 359(6379):1037-1042. PMC: 5947856. DOI: 10.1126/science.aar3246. View

Krishna S, Lowery F, Copeland A, Bahadiroglu E, Mukherjee R, Jia L . Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 2020; 370(6522):1328-1334. PMC: 8883579. DOI: 10.1126/science.abb9847. View

10.

June C, OConnor R, Kawalekar O, Ghassemi S, Milone M . CAR T cell immunotherapy for human cancer. Science. 2018; 359(6382):1361-1365. DOI: 10.1126/science.aar6711. View

11.

Rosenberg S, Restifo N . Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348(6230):62-8. PMC: 6295668. DOI: 10.1126/science.aaa4967. View

12.

Liao W, Lin J, Leonard W . Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013; 38(1):13-25. PMC: 3610532. DOI: 10.1016/j.immuni.2013.01.004. View